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INTRODUCTION

Advances in the treatment of Human Immunodeficiency Vires have dramatically

improved survival for those infected. Death rates from HIV infection declined by 47%

from 1996 to 1997 and HIV dropped from the leading cause of death in 1995 to the fifth

leading cause of death in 1997 in those in the 25-44 year age range (CDC, 1998).
Antiretroviral medications developed within the last five years have resulted in suppression

of viral replication, heretofore incomprehensible.

However, this progress has been

accompanied by a monumental challenge to those living with the infection as well as those
involved in their treatment and enthusiasm for substantial and real progress has been

subdued amidst fears that clinical gains may be short lived.
Combinations of medications used to treat HIV are commonly known as Highly

Active Antiretroviral Therapy or HAART. These combinations are complex, requiring large

numbers of pills and very specific instructions for their use. Unfortunately, HAART

regimens, like other treatmems for chronic diseases, also demand a level of a certain level
compliance and incur serious consequences when adherence levels are too low. Nonadherence is a leading cause of the development of resistant vires and can lead to crossresistance with other HIV medications rendering them ineffective. Not only are there

personal consequences for the individual whose vires is no longer successfully controlled
by his medications but the potential for transmission of resistant vires represents a serious
potential public health concern.

The objectives of this paper are to develop an intervention to maximize HAART
medication use.

It is this author’s belief that medication adherence requires a

multidimensional and multidisciplinary effort. It is also her belief that it is difficult, if not

impossible, to either evaluate or affect some patients’ adherence in isolation from their daily
life. The magnitude and gravity of the problem requires the development of a new member

of the healthcare team, who would become the centerpiece of the adherence effort. This
health professional would be specifically trained to evaluate knowledge, lifestyle, adherence
behavior and motivation as well as to provide information, teach necessary skills, and serve
as a liaison between the patiem and provider.

The outcomes for this intervemion are:

To support and improve antiretroviral medication adherence
To demonstrate objective HIV disease therapeutic benefit by improvemem in viral
load, CD4 cell counts, and clinical outcome
To decrease morbidity and mortality in those with HIV infection due to inconsistem
pill taking behaviors
To alleviate existing constraims and burdens placed on HIV providers and the health
care system
To lower HIV-related health care costs due to decreased hospitalizations, fewer
emergency room visits, and decreased episodes of crisis health care management
To reduce the incidence of antiretroviral resistant HIV and to decrease the potential
for its transmission.

To this end, this thesis will presem the fundamemal principles of HIV and
illustrate the relationship of inadequate viral suppression, non-adherence, and

antiretroviral resistance. A review of the adherence literature, as well as literature on
behavioral models will then be assimilated to develop the practice and principles of a

medication manager. A curriculum to train medication managers will be proposed and a

description of responsibilities of this new health professional will be presemed.

HIV INFECTION
HIV Pathogenesis: How the Virus Works

HIV, like all viruses, is totally parasitic. It cannot reproduce independemly and
must invade a host cell and use that cell’s machinery in order to replicate. The process of

viral replication in various host cells in the body is called the Viral Life Cycle. The single

strand of RNA in the core of the vires must be transcribed into DNA in order to infiltrate
the host cell’s DNA and for viral replication to occur. This transformation from viral RNA
to viral DNA occurs with the help of the enzyme contained in the viral core called reverse

transcriptase. The viral DNA is then able to infiltrate the host cell’s DNA to usurp the
host’s genetic machinery in order to replicate its own genetic blueprint. The long chain of
viral products that are produced in the cell nucleus must then be cut and reassembled to
construct a new viral particle. This is done with the help of the viral protease enzyme. The

host cell is thus transformed imo an HIV vires factory, producing viral proteins instead of
the cell’s normal regulatory proteins.

Relentless viral replication in susceptible cells is the primary mechanism of immune

system destruction in HIV infection. Ho (1995), Wei (1995), Coffin (1995) and others have
demonstrated a highly dynamic process with a rapid tumover of vires, even in

asymptomatic patients. The number of virions (viral particles) present in the body at a
given time is a result of the battle between the vires and the immune system. The number of
virions detected is referred to as the viral load.

The Surrogate Marker for Effective Medication Adherence: Viral Load

The value of following a patiem’s viral load has been well-established (Mellors,

1996, Mellors, 1997). To underscore the role of the amount of vires in the body Coffin
introduced the analogy of a train approaching a cliff, in which the CD4+ cell count is the
distance to the precipice and the viral load is the speed of the train (Coffin, 1996). The total
amount of vires detected on viral load testing is in fact a surrogate for how quickly the vires
is actually replicating.

How quickly the vires is replicating determines how quickly

valuable CD4+ lymphocytes are being destroyed and how hard the immune system must
work to replenish the store of immune cells. Over time, the T cell replenishing system tires,

whole populations of T cells, like memory cells, which recognize antigens, are wiped out
and HIV gains control.
Mellors et al. (1996, 1997) analyzed viral load data from the Multicenter AIDS

Cohort Study (MACS) to demonstrate the ability of viral load, with and without CD4+ cell

counts, to determine the risk of progression to AIDS and death.

In his analysis Mellors (1996) used frozen and saved plasma specimens from
differem timepoints during the MAC study to obtain viral load measurements. He added

the viral load data to CD4+ cell results, and to clinical endpoim and survival data from 180
of the 209 HIV-infected gay or bisexual men enrolled in the Pittsburgh MACS site. The

relationship between baseline viral load (the viral load performed on saved specimens that
were obtained at the patients first visit) and baseline CD4+ T cell counts were examined.

The results of Mellors research are summarized in Table 1.

Table 1" Conclusions of Pittsburgh MAC Cohort Study: (Mellors et al., 1996).

The risk of AIDS and death was directly related to plasma viral load.
There was a significant increase in the rate of progression to AIDS in those with higher
viral loads.
There was a significant difference in median time to death in those with _< 10,190
copies versus _> 10,190 copies per ml.
Individuals with a 3 fold higher viral load face a 1.5 times greater risk of death within
10 years.

Measures of viral load are generally accepted as markers of viral control, successful
treatment, or HIV treatment failure. Viral load measurements can now detect viral levels to
as low as 20 copies per milliliter of plasma. The succession of measurements of viral load

provides both the individuals with HIV and their providers of care with a snapshot of viral
activity in a given

momem. High

viral loads are indicative of a high rate of viral

replication.

Numerous clinical trials have shown that effective therapeutic regimens drive vires
to levels below the level of detection in plasma, which occurs when viral, replication is

inhibited. (Wong, 1997). However, it is still premature to know what the natural history of

viral replication over time will be in patients who are adherent. It is hoped that natural

history can be influenced by an ongoing assault with potent antiretroviral therapy. However,
evidence has surfaced that even in the presence of potent antiretroviral therapy, replication

competent virus can still can be found in lymph nodes and resting cells This casts a cloud of
uncertainty on current successes. Curremly, we have reason to believe that viral levels
which rise to detectable levels after successful suppression point to medication failure. HIV
medication failure is principally a function of the developmem of viral mutations, arising

from the vires’ natural instinct to survive. Given that adequately suppressed vires cannot
mutate and that partial suppression favors mutations and the development of resistance,

increases in viral load have also become recognized as a flag for poor adherence to

medication regimens. It is with this awareness that the field of medication adherence in

HIV treatment has flourished.

How Resistance Happens

As stated previously, viral genes carry the blueprint to direct the formation of HIV
specific proteins (long chains of amino acids), including enzymes, that are contained in a
single HIV particle. (Cooper, 1997). The nucleotide sequences comained in the genes
specify the order in which the amino acids are incorporated imo proteins. This configuration
is the basis for medication developmem.

Studies published in 1995 provided valuable insight into the kinetics of HIV as well
as the mechanisms of viral variation and resistance. In particular, two observations that year

have direct bearing on our understanding of resistance; first that HIV replicates at a

remarkable rate (Ho et. al, 1995; Wei et. al, 1995). An estimated ten billion copies of virus
are made each day (Coffin, 1996). The second relevant observation is that a key enzyme in

viral replication, reverse transcriptase, lacks an essential proofreading mechanism and is

thus very error prone in its replication efforts. It has been estimated that each time the vires

replicates at least one amino acid substitution occurs, changing the vires slightly from its

progeny each replication cycle (Coffin, 1995).
Therefore, viral variation and the resultant genetic diversity in HIV infection are a
natural consequence of both high levels of viral replication and an error prone reverse

transcriptase enzyme. In fact, the higher the viral replication rate the greater the number of

errors made. Even in the absence of drug therapy viral mutation is inevitable given the

nature of HIV dynamics.

Generally, these mutations represent only a small percemage of all the vires found
in one individual. Early on in infection there is little evidence of mutation. This virus is
said to be "Wild Type" or in an unmutated state, like that found in nature. If mutated vires
is not amplified under conditions of drug pressure, it may never be recognized, since it will

exist only as a small percentage of a larger species. (Wainberg and Friedland, 1998) Over

time, however, if the vires is allowed to replicate the virus becomes increasingly diverse as

ongoing changes become incorporated imo new vires. It is precisely these mutations that
result in changes in the viral susceptibility to a particular drug. Substitutions in the order of
amino acids comained in the viral enzymes, protease and reverse transcriptase, confer

reduced susceptibility, to the classes of medications, protease inhibitors and reverse

transcriptase inhibitors.

Transmission of Resistant Viral Strains

The initial report of transmission of HIV, resistant to AZT, was published in 1993

(Erice et al.). In a more recent international study of viral resistance involving Swiss,
Australian, and US patiems, 8-11% of Swiss and Australian patients and 6-8% of American

patiems were resistant to AZT upon seroconversion (Mayers, 1995). Transmission of
resistance to 3TC and nevirapine has also been reported (Conway, 1997). In a recent study

presented at the Twelfth World AIDS conference Hecht (1998) reported the transmission of
vires resistant to

AZT, 3TC, indinavir, ritonavir, saquinavir, and nelfinavir, detected in a

newly infected, untreated individual. This confirms the assertion of Wainberg and

Friedland, (1998) that transmission of vires resistant to all classes of antiretroviral agems is
likely.

The Effect of Antiretroviral Treatment on Viral Replication and Resistance

Potent combinations of antiretroviral therapy offer the greatest opportunity for
durable suppression of viral replication. Several important discoveries have been made
which support this hypothesis. First, the higher the trough level (the level at the lowest

point) of plasma concentrations of medications, the more slowly resistance is likely to

emerge (Molla, 1996). The second is that the lower the viral load is driven, the longer the
viral response to medication will last (Kempf, 1998).

In a patient who is who is taking medication as prescribed (adherent) and whose
viral replication is minimal, viral mutations are also minimal. Conversely, in a patient who
is not taking their medication adequately, there is ongoing replication and consequently

increasing amounts of mutations develop.
Partial treatmem favors the development of mutations by inhibiting vires that is
sensitive to the medication and giving drug-resistant strains a competitive advantage. In

this way, medication is said to exert selective pressure on the vires, allowing one or more

formerly uncommon, mutated HIV strains to multiply while inhibiting dominant natural
strains that are sensitive to treatment.

When antiretroviral medications are developed they are designed to inhibit the vires

replication by imeracting with the vires at a particular point, called the active site. The
active site is located in key positions in the protease or reverse transcriptase enzymes.

When mutations occur in the active site of the vires, the effectiveness of their corresponding
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medications, reverse transcriptase inhibitors or protease inhibitors, is lost. Non-adherence to
antiretroviral therapy is the shepherd for this cascade of evem.

ANTIRETROVIRAL THERAPY FOR HIV INFECTION
The Challenges in HIV Medication Regimens

The challenge of HIV medication adherence is set against a backdrop of harsh
realities about the regimens themselves. Numerous studies have shown that successful
inhibition of HIV viral replication requires not single therapy but combinations of a
minimum of three medications (Hammer, 1997). An individual may have to consume as

many as 20 to 25 pills, to be taken each day, often divided over two or three doses at
differem times during the day. Besides the large number and frequency of pills, there are

also other factors, which make currem medication options difficult to take. Individuals who
are being treated for HIV infection have to contend with a plethora of medication side

effects, some of them life threatening, disfiguring, or reducing quality of life. Currem
formulations of HIV medications also have numerous interactions with other medications,
are altered by the presence or absence of food and some even have specific storage

requirements. This obligates patients to adhere to strict instructions concerning the timing

of their medications and forces individuals to structure their lives around their pill taking.
The ever-present reality of drug interactions demands a strict awareness and knowledge of

the potential conflict with other seemingly harmless medications. Conflicts with other
medications competing for the same mechanism of drug metabolism can either lead to

inadequate levels of one of the medications or dangerously high levels of one of them.
There are serious consequences in either case; one facilitating sub-optimal drug levels and
increased viral load and the other increasing the likelihood of toxicity.
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Recognizing the delicate balance between toxicity and adequate therapeutic
medication levels, difficult medication instructions must be followed precisely. The process

of drug developmem aims to identify the most efficacious and safest medication doses but
this also results in medications which have a narrow therapeutic range. A minimum amount

of medication must be ingested in order to assure adequate therapeutic blood levels. For

example, in hypertension it has been determined that blood pressure begins to fall only
when patiems take more than 80% of their medication. Based on hypertension experience

many surveys of HIV medication adherence have used the 80% cutoff as a significant
measure of adherence.

In fact the question of how much adherence is enough in HIV

treatment has not been answered but is assumed to be an unequivocal "a lot" (Woodward et

al., 1998).
The psychological barriers to HIV medication taking are complex and an in-depth
review could be the subject of an emire thesis. However, there are several issues worth

memioning. One issue is that pill taking is in itself a constant reminder of the devil that
threatens the lives of people with HIV, presenting those infected with the intrinsic challenge

of facing their disease on a daily basis. Those who have not imegrated HIV successfully
imo their lives may have difficulty accepting the burdens and reminders in treatment. In a

study presented at the Twelfth World AIDS Conference in Geneva, Switzerland
psychological well being was explored as a factor in medication adherence. The study
concluded that "feeling comfortable and well cared for" and having a "meaningful life" are
factors associated with medication adherence (Holzemer et al., 1998). It has also been

theorized that an understanding of the complex relationship of individuals with HIV to their
environment must be understood in order to understand their compliance with care,
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including medication adherence, (Bennet et al., 1998).

Thus, those with HIV are expected to take their pills faithlly, in spite of the
enormous challenges presented by complex regimens, in the face of environmemal and

psychosocial barriers and despite the nature of human failings.

Antiretroviral Therapy Mechanisms of Efficacy

It is well known that the efficacy of any therapeutic regimen depends on adequate
blood levels of individual medications producing a desired physiologic response.

The

efficacy of antiretroviral regimens used to treat HIV infection depends on adequate
antiretroviral levels to inhibit viral growth and minimize the consequences of HIV disease.

Adequate suppression of the vires interrupts the viral life cycle and ultimately diminishes
the rate of infection of uninfected cells in the body. Suboptimal levels of antiretroviral
medication lead to incomplete viral suppression and invites the outgrowth of less common

mutated viral species. Although there are a number of variables which impact achieving

adequate blood levels, such as absorption and drug imeractions, adherence remains a
necessary elemem in the equation.

Profile of Highly Active Antiretroviral Therapy (HAART): The Landscape of Viral

Regimens
There are currently 15 approved medications for the treatment of HIV infection.
These medications, their dosing, side effects and special instructions are found in Table 2.
The addition of protease inhibitors and non-nucleoside reverse transcriptase inhibitors to
antiretroviral options has dramatically increased regimen complexity. A number of these
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medications have specific gastric requiremems (full stomach versus empty stomach) and
use the p 450 pathway for liver metabolism.. The liver enzyme p450 is responsible for

the metabolism of many drugs. Medications that are described as an inducer of p450 can
increase the metabolism of other drugs and medications that are an inhibitor of p450 can

slow the metabolism of other drugs that share the same metabolic pathway. This
translates to slower excretion (increasing exposure to the drug) or more rapid excretion

(inadequate amount of exposure to the drug). Drugs that induce or inhibit metabolism
must be taken cautiously with other medications that are metabolized in the same manner.

Table 2 is followed by some typical antiretroviral regimens.
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Examples of Antiretroviral Regimens Currently in Use:
1. One PI and 2 nRTIs
2.
3.
4.

5.

Example: AZT/3TC/indinavir (8 or 14 pills per day) (TID regimen)
Example: ddI/d4T/ritonavir (13 pills per day) (BID regimen)
One NNRTI and 2 nRTIs
Example: efavirenz/d4T/3TC (9 pills per day) (BID regimen)
Two PIs with 1 or 2 nRTIs
Example: ritonavir/saquinavir/ddI/d4T (27 pills per day) (TID regimen)
One PI and 1 NNRTI with 1 or 2 nRTIs
Example: nelfinavir/efavirenz/combivir (14 pills per day) (TID regimen)
Three nRTIs.
Example:d4T/3TC/abacavir (less potent regimen) (6 pills per day) (BID regimen)

MEDICATION ADHERENCE IN THE
TREATMENT OF CHRONIC DISEASES
What Is Adherence And What Have We Learned About Adherence and Nonadherence Thus Far?

"The physician should keep aware of the fact thatpatients often lie when they state they

have taken certain medicines"(Hypocrites, circa 400BC)
The extent to which a person’s behavior coincides with medical or health advice is

generally referred as adherence or compliance (Haynes, 1979). For a precise distinction
between the two, Webster’s Dictionary was employed. Adherence implies "attachment to a

person or cause; sticking fast, to stay firm in supporting or approving". Compliance, on the
other hand is defined as "giving in to a request, wish, or demand; acquiescence; a tendency
to give in readily to others; yielding, submissive, or obedient"..
Given the implication of control that is connoted in the word compliance and the

evolution in health care toward patients as consumers of services, rather than passive

recipients of doctors orders, one can see how adherence seems to have emerged today as the
more appropriate term.

Some have even gone so far as to describe the effort as a

therapeutic alliance, but for the purposes of this paper adherence will suffice. Making light
of this debate however, is not meant to detract from the intention of this author to contribute
to the notion that the effort is necessarily a partnership. In this partnership the patient

contributes expertise on his life and worldview and the provider contributes expertise on the
scientific basis for treatment.
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Even if there was agreement on what it should be called, our current definition of
adherence is quite subjective and generally implies that patients must take all their

medications, all of the time. Several studies in fact have shown that 100% compliance is not

always necessary. Friedland (1998) uses the term "pharmacologic forgiveness" to describe
therapies that are chronically administered and are known to have a long duration of effect
after dosing, allowing for lapses in adherence. Friedland also asserts that these medications

may also have a large therapeutic-toxic ratio. The definition of adherence could be clearer if
we consistently knew the poim below which the desired therapeutic result is unlikely to be

achieved. In one study conducted to determine this, Fletcher demonstrated that blood

pressure falls significantly when patiems take more than 80% of their medication (Fletcher,

1974). In an earlier study, Markowitz demonstrated that oral rheumatic fever prophylaxis
could be achieved if children took at least 33% of their penicillin (Markowitz, 1970)

Unfortunately, most medications are not developed with minimum requirements in mind
and therefore cut off points are rarely available. Even when studies have attempted to
define minimum exposure necessary for adequate blood level, results often did not coincide
with levels needed for clinical effectiveness (Gordis, 1976).

Although for antiretroviral therapies there has not been concrete documentation of
minimum adherence, inferences have been made.

It is also possible that differem

antiretrovirals with differing characteristics may not all share the same threshold. Authors

of a report of the effects of high doses of the protease inhibitor saquinavir noted that in a

small subgroup of patients studied for adherence and mutations, imerruptions in dosing for
as short as three days resulted in immediate viral load increases (Schapiro et al., 1996).

Significantly, viral load increases occurred even before mutations appeared in the plasma of
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the study patiems. The authors interpret their findings to suggest a relationship between
even brief periods of non-adherence and increases in plasma RNA levels. Unfortunately, a

failing of this study was the lack of accompanying pharmacokinetic data, which would
enable us to understand pharmacokinetic factors of increased viral loads.
Whether it is referred to as adherence or compliance, the medical literature is rich in
information concerning the topic for a variety of chronic diseases including hypertension,

diabetes, asthma, arthritis, and cardiovascular disease. In fact, a recem medline search in

preparation for this thesis netted 15,650 articles since 1966, under the search topic
adherence or compliance.

Documentation of the Problem: Prevalence Rates of Non-adherence

The incidence of non-adherence varies across circumstances. Non-adherence rates

for prevemion regimens range 30-40% overall, while rates for short term curative regimens
are a slightly better 20-30% (Haynes,

1979). The rate of non-adherence for chronic diseases

or long term regimens consistently averages around 50%

(Sackett and Snow, 1979; Becker,

1985; Eraker, Kirscht, Becker, 1984). A striking example of non-adherence is offered by
Vincem (1971) who studied patiems being treated for glaucoma. These patients were told

that "they must use eye drops three times a day or they would go blind." Only 42% of the

patiems took enough medication to prevent blindness. At the point where patients were

becoming blind in one eye, their adherence only improved to 58%, leading some to
conclude that non-adherence is a form of self-destructive behavior (Faberow, 1986).
Given that we often do not know what constitutes adequate adherence we are left

with a subjective and often ambiguous term. Having said that, non-adherence takes many
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forms, each preseming the provider with a unique challenge in caring for their patient.
Non-adherence is an issue that transcends all health-related behaviors including medication

taking, keeping medical appointmems and health related behavioral changes. For the
purposes of this paper, only non-adherence to medications will be reviewed in detail. Even
within medication non-adherence the following deviations have been described:

1) Not filling a prescription or filling a prescription late, causing an interruption in
dosing (also known as a "drug holiday")
2) Not taking the correct medication dose
3) Not adhering to gastric requirements (with or without food)
4) Not adhering to instructions concerning concomitant medications
5) Skipping doses
6) Taking doses at the wrong time
7) Not finishing the prescription as instructed
Influences on Adherence: Factors and Barriers Contributing to Non-Adherent
Behavior in Chronic Diseases

The factors, which explain variances in adherence, have been the subject of much
research over the years. Haynes (1976) conducted a comprehensive review of more than
200 potemial variables in relation to adherence. Taylor et al. (1978) idemified risk factors of

noncompliance in antihypertensive therapy and Haynes (1979) followed with a second

comprehensive review of determinants of noncompliance in which he detailed determinants
idemified in 185 journal articles. Determinants of adherence are generally clustered into

several main categories" medication factors; provider factors; disease factors and patient
factors. Meichenbaum and Turk (1987) noted that although these factors are generally
discussed independently they are substantially interrelated.

The findings of the large

comprehensive reviews cited above and others are summarized below:
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Medication Factors

Duration of Therapy

The duration of treatmem has been found to be negatively associated with

adherence, decreasing with increasing duration on therapy. Chamey (1972) reported that
diabetics who had been treated for 1-5 years demonstrated a 30% error rate which rose to an

80% dosage error rate in patients who had been treated for more than 20 years. Abemathy

(1976) reported that 19% of patiems treated for mild hypertension discontinue therapy in
the first 2 years. Furthermore, the comparison of a 50% medication adherence rate for longterm treatment versus 77% rate of adherence for short term treatment is highly supportive of

the influence of duration of treatment (Haynes, 1979).
Regimen Complexity

As a regimen becomes more complicated, compliance declines (Becker and
Maiman, 1980, Haynes, 1979). Hulka et al. (1975) demonstrated that patients with diabetes
or congestive heart failure had less than 15% medication errors when

one

drug was

prescribed; 25% medication errors when two or three drugs were prescribed; and had
greater than 35% when five or more drugs were prescribed. In Haynes’ 1979 review,
eleven studies were reported to have found a significant negative association with the
number of drugs in a regimen (Brand et al, 1977; Clinite, 1969; Davis, 1963; Francis et al.,

1969; Hemminki, 1975; Hulka, 1966; Latiolais, 1969,Malahy, 1966; Neely, 1968; Parkin,

1976; and Weintraub, 1973). Medication regimens are further complicated by multiple
dosing schedules. Malahey (1966) and Brand (1977) demonstrated that the number of doses
per day was a stronger predictor of non-adherence than number of pills per day. The notion
of three times a day versus every 8 hours can be confusing even applied to a single
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medication. This confusion can be multiplied by the addition of several drugs. Svarstad

(1976) reported that three out of four times patients were not given specific instructions
concerning dosing. Meichenbaum (1987) suggests that complex regimens overwhelm

people who then use one or more non-adherent behaviors to cope.
Side Effe c ts

There is little support in the general chronic disease literature to relate medication
side effects to adherence. In the Haynes review there were no studies reporting significance

for this variable further in studies of patiem surveys of non-adherence Haynes (1979)
summarized that only 5-10% of patiems even memioned side effects as an issue and none

felt it was an important factor in non-adherence. However, side effects will be addressed
more fully as a determinant of antiretroviral adherence in HIV infection.

Regimen Intrusiveness
Meichanbaum (1987) asserts that the demands placed onthe patient’s life,

disruptions in daily routines and lifestyle, represent an important impedimem to taking
medication.

The degree to which behavioral change is required is determined by a

combination of medication factors and the patient’s perception of the inconvenience of the

regimen.
Patient Factors

Demographic Features ofPatients
The literature does not support assumptions that adherence can be predicted by any

demographic variables. Haynes (1976) reviewed studies of demographic characteristics and
identified few studies that found positive associations with medication adherence using a

scoring system that assigned ascending numerical values for progressively rigorous
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methods. Far more studies found no association including factors such as social class, age,

sex, education, and marital status.
Social Isolation and Social Support

The positive influence of social support and the negative influence of social
isolation have been well documented. Oakes (1970) reported that patiems who believe that

family members expected compliance were more likely to comply. In a study conducted by

Porter (1969), living alone was the most significant influence on adherence among
chronically ill medical patients. In a review of 19 studies conducted by Baekeland and
Lundwell (1975) low social support was a significant finding in each study reviewed.

Stability and family support also correlated with adherence (Becker and Green, 1975).

Thus, the availability of patient support should be discussed and, when possible, a family
member or close friend should be included in the adherence process.
Patient Involvement

Various behavioral models empirically support active patiem participation, in

planning and decision-making concerning treatmem.

Inclusion of the patiem as a

collaborator increases commitment and enhances motivation. The patiem is more likely to
adhere when they set their own goals and feel supported in their efforts, rather than judged
for their failures.
Health Beliefs and Attitudes
The Health belief model developed by Rosenstock suggests that patiem’s

perceptions of the severity of their illness and the benefits of the treatmem influence health
behavior. Taylor et al. (1978) demonstrated that the relationship of health beliefs to
behavior seems to reach statistical significance after patients have been treated over time.
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Health beliefs of steelworkers were assessed during blood pressure screening and again

after 6 and 12 months of therapy. Beliefs before treatment were unrelated to adherence
behavior at 6 and 12 months after therapy. However, after treatment, significant correlation
was documented for beliefs concerning severity of illness, negative attitudes toward drug

taking, and the worry that illness would lead to dependency. This suggests the importance
of discussing health and treatmem beliefs after the patiem has had experience with the

regimen.

Locus of Control
Individuals who view themselves in control of their lives, motivated by an imemal

locus of control, are more apt to comply with treatmem. Studies of hypertensive (Lewis et
al. 1978), and hemodialysis patients (Poll, 1980) demonstrate a positive association with
adherent behavior and a sense of internal control. Non-adherence may also

represem the

patiems attempt to gain back control over the illness or the treatment (Meichanbaum, 1987).

Knowledge and Understanding
Knowledge does seem to influence decisions but the literature is conflicting on
whether or not it has a significant relationship to medication adherence. Studies have

reported varying results that range from no relationship (Kirscht et al., 1981, Cummings et
al., 1982) to a positive effect (Rosenberg, 1971, Maiman et al., 1979). One fundamental

problem in evaluating the relationship of knowledge to behavior is that knowledge is an
ambiguous and inconsistently used term. Also, information is often "given" in terms that
patients may not understand, in a language that patients may not understand or in the
absence of any measure of comprehension. Misunderstanding has been demonstrated for
dosing terms such as "every 6 hours" (Mazzullo, 1976), and terms such as "evening" or
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"with food" may be misinterpreted. Svarsted (1976) reported the results of a study to

analyze the influence of information given at a neighborhood health cemer. Results
highlighted many problems in the "giving" of important medication information. Patiems
were prescribed medications without accompanying verbal or written information and

patients were rarely given information about regimen dosing and duration. In this study 17
% of patients with poor understanding of their regimen were adherent versus 60 % of

patients with accurate information.
Patient-Provider Factors

Relationship with Provider
Several aspects of the patient’s relationship with the provider have been shown to

significantly influence adherence. Better adherence is associated with physicians giving
explicit, clear, and appropriate instructions, and timely positive feedback (Davis, 1968).
The length of time a physician spends with a patiem also has a positive effect. Patiems who
feel satisfied with their visit and have a provider with whom they can communicate have

better adherence (Meichenbaum, 1987). Adherence is compromised when patiems feel
their expectations are not met or they experience the physician as unfriendly, not empathic
or rushed (Davis,

1968). Strauss et al. (1984) asserted that there is a fundamemal

discrepancy between the patiem and provider, maimaining that providers judge medication
regimens on their medical worth and patients judge regimens on a social basis. Providers
who lack an appreciation of the impact of medication taking on a patiem’s life may find
themselves alienated from their patiem.
Increased Patient Supervision
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There is a clear and strong correlation between the degree of supervision and

adherence. Wilbur (1969) demonstrated the benefit of regular home visits to hypertensive
patients by a public health nurse. Eighty-eight patiems were followed for two years.
During this time the percentage of patients who accepted treatment for their hypertension
increased from 25% to 85%. Relevant findings on the influence of increased patient

supervision are that adherence improves when the frequency of out patiem visits is

increased, when home visits are added and when the patiem’s family is involved in
supporting the their adherence.
Disease Factors:

Adherence is more likely for short term, symptomatic illness (O’Brien, 1992).
Patients with chronic illness must adjust to the fact that no matter how diligent they are

about compliance they will never be rewarded with a cure (Cameron and Gregor, 1987).

When chronic illness is asymptomatic the patient must arrive at health decisions without the
"benefit" of cues, which provide motivation for treating illness. Taylor (1978) and others

(Meichanbaum and Turk 1987) assert that adherence is lower in the absence of symptoms,
which serve as a medication reminder. Taylor (1978) reported on 416 patients surveyed on
their antihypertensive adherence.

Fifteen percent revealed "they had stopped taking

medication because they felt they did not need it."

A Review of Strategies to Improve Medication Adherence in Chronic Diseases
Although correlates of adherence have been idemified, the literature is surprisingly
weak and sometimes contradictory on effective measures to improve adherence. A review
of the hypertension data from 1960-1991 demonstrated that despite years of efforts to
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improve adherence to antihypertensive medications only 29% of the 50 million people in
the U.S. who are hypertensive have their blood pressure controlled (Burt, 1995). Adherence
to long term regimens is more difficult to achieve than for. short-term regimens and is

complicated by the evidence that adherence declines when interventions are withdrawn

(Harris, 1971).

Reviews of medication adherence to regimens for chronic diseases

emphasize that no single strategy is effective in improving adherence.
Behavioral modification techniques have been employed with success in changing

behavior. Tailoring is the process of fitting prescribed regimens to patient routines and
circumstances. Tailoring recognizes the needs and the uniqueness of the individual and

addresses issues of disruptions in lifestyle. Contingency contracting refers to the process of

negotiating on specific behaviors and formalizing a commitment to following them.
Reminders are a useful cue for pill taking and may range from phone calls to new electronic

beepers programmed for dosing times.

Reminders may be especially helpful for

asymptomatic patients who are not cued to take their medications by symptoms.

Haynes (1976) demonstrated the utility of these modalities in an imervemion for
improving antihypertensive adherence using behavior modification principles. The
intervemion included self-monitoring, tailoring of medications to patiem schedules and

positive reinforcemem. They concluded that there was a 21% increase in adherence in the
intervention group compared to a 1% decrease in controls over time.

In a review of adherence interventions, Haynes (1987) stresses the need for
multifaceted imerventions which may include: enhancement of social support, written

instructions, patient self-monitoring, contingency contracting, rewards or reinforcemem,

group discussions, and increased supervision. In a later review by Haynes et al. (1996),
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randomized trials of adherence imervemions which met a rigorous standard were evaluated.
Criteria for inclusion of the studies in the Haynes review required that the study used one or
more measures of adherence, one or more measures of treatment outcome, at least 80%

follow-up of each group studied, and at least 6 months of follow-up for long term studies.
Between the years of 1993 and 1995 four medline searches were performed and 1553
citations were reviewed. Two hundred and fifty two articles were deemed worthy of full

review however, only 13 randomized clinical trials met all the criteria for inclusion in the

analysis. Ultimately, the authors concluded that even the most effective intervemions did
not lead to substantial improvements in adherence when used alone.

Four of the interventions reviewed by Haynes produced significant influences on
adherence as well as outcomes"

Bailey (1990) demonstrated positive effects on the adherence of 132 patiems taking
asthma medications through the combined imerventions of a pamphlet, workbook,

counseling, phone follow-up, support group and reinforcemem of adherence. Colcher

(1972) improved the adherence of short-term treatmem for strep throat with counseling plus
written instructions on how to take pills. Logan (1979) showed a significant effect on

adherence with worksite nurses, tailoring medication regimens, self-monitoring of blood

pressure and rewards for higher adherence and lower blood pressure.

Strang (1981)

improved adherence with family therapy for patiems with schizophrenia.

Other

intervemions improved adherence but did not meet the rigor of improving outcomes. These
included decrease in medication frequency (Baird, 1984) and other combinations of

intervemions which included tailoring and increasing support and supervision.
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In a recem meta-analysis, Roter et al. (1998) reviewed 153 studies of measures to
improve adherence. She classified interventions by theoretical basis in categories of

educational, behavioral and affective interventions. Roter concluded that each of the
interventions had a small effect size. Roter (1998) concurs with Haynes’ conclusion that

"no single strategy or programmatic focus showed any clear advantage compared with
another." Significantly, the most powerful imervemions included the combination of three
modalities: educational, behavioral, and affective.

She cites the need for much more

information giving and positive talk and less questioning. She also reaffirms that the length

of the visit and the degree of collaboration with the patiem are important characteristics of

adherence support.
Table 3 summarizes adherence intervention strategies and principles from the
chronic disease literature.
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STRATEGIES FOR IMPROVING MEDICATION ADHERENCE
Table 3: (Adapted from Miller, 1997)

REFERENCE
STRATEGIES"
EDUCATIONAL
Knowledge is a necessary but not sufficient component of behavior Eraker, 1984
change
Information should be given in clear non-technical language
Eraker, 1984
accompanied by written instructions which include information on
dosing frequency, medication duration, potential side effects
Pratt, 1995
Combined use of written and verbal instruction may enhance
adherence

Return demonstration of information (i.e. how to take pills) helps
to evaluate comprehension
BEHAVIORAL
Tailoring treatment to habits and not habits to treatment improves
adherence
Simplifying regimens to once or twice daily and eliminating
unnecessary medications increases adherence
Adherence enhancement requires the use of a combination of
behavioral interventions (i.e. contracting social support, goal
setting)
Maintenance of most behaviors declines over time; constant
questioning and follow-up are essential to assure adequate
adherence

PATIENT-PHYSICIAN COMMUNICATION
Patient satisfaction with the provider is correlated with adherence
The likelihood of adherence is increased when the patiem’s
expectations of a visit are matched by what actually occurs
Sincere warmth and concern, responding to questions, desire to
influence adherence, and spending additional time with patients are
important physician attributes
Physician awareness and training about adherence have positively
influenced rates of patient adherence
Increasing supervision of patients through home visits, more
frequent appointments, etc. improves adherence
COMBINATION STRATEGIES
Combination imervemions which include an education, behavioral,
and affective components have the strongest effect on adherence

Miller, 1995

Haynes, 1976
Rudd, 1995

Haynes, 1987
Dunbar-Jacob,
1991

Haynes, 1976
Becker, 1985

Pratt, 1995
Svarstad, 1976
Wilber and
Barrow, 1969.

Rotor, 1998

MEDICATION ADHERENCE IN THE
TREATMENT OF HIV DISEASE
The literature on adherence to antiretroviral therapies in the treatment of HIV
disease is relatively limited as treatment itself is still in relative infancy.

Imerest in

medication adherence in the last two years has blossomed but practice has not yet evolved
to routinely include adherence assessment and interventions. Imerventions are under study

while clinicians and behaviorists learn to appreciate each other’s strengths.

Williams

(1997) asserts "that it is the noncompliance of the providers that is reflected in our failure to
implemem adherence imerventions that have been demonstrated to be effective." The study
of adherence in antiretroviral therapy is still in the fact-finding stage. There have been few
formalized research projects published to date. Surveys have been conducted in an effort to

idemify what is unique about adherence to HIV therapies. These mostly search for answers
to why people don’t take life-saving medications religiously. This section will not reiterate

issues already presented but will specifically review the efforts to characterize the problem

of non-adherence to antiretroviral therapy and the ongoing efforts to address the issues.

Documentation of Medication Non-adherence in HIV Disease

Given the impact of adherence on HIV care, many recent studies to characterize the

prevalence of the HIV adherence problem have been conducted. HIV, like other chronic
manageable diseases shares similar rates of non-adherence. A number of adherence patient
surveys were conducted during 1998 and many of these were presented at the Twelfth World

AIDS Conference, Geneva Switzerland. Some of these are summarized in Table 4.
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Table 4: Surveys of Patient Adherence to Antiretroviral Therapies

N

Chesney
(#281)

665

% of Patients with
Incidence of NonAdherence Within the
Last Month
>43%

Gallant and Block

359

43%

198

56%

135

22%

1200

35%

103

46%

Study

(1998)
Johnston

(# 32389)
Jiminez-Nacher et
al. (#32350)
Nakashima

(# 393/32326)
Williams et al.

(# 32374)
Walsh et al.

114

59%

(#12298)

Findings

26% missed a dose the day
before. 43% missed a dose
.in the past week.
25% admit to nonadherence to the regimen on
the preceding day.
31% had chosen not to take
all drugs in the regimen and
41% took the medications

irregularly
56% of patients took >80%
of prescribed pills
9% indicated they rarely or
never took their medications
54% took > 97% of their
medications
Only 25% of patients
admitted <80% adherence

The individual and public health costs, which are incurred as a result of insufficient

pill adherence, have not been calculated. However, the development of resistance to an
individual medication and the subsequent elimination of other medications in the same class

through cross-resistance have been documented (Condra, 1995, Molla 1996).

The

individual consequences of insufficient pill adherence are inadequate control of viral

replication. Drug failure can lead to accelerated progression of HIV illness and increased
mortality.

The public health consequences may result in an epidemic of resistant HIV

strains. Numerous cases of the transmission of resistant strains of HIV have already been

reported in the literature (Erice and Mayers, 1993, Imrie et al, 1997, Quigg, 1997) and the
full implications of this have not yet been realized.
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Reasons for Non-Adherence to Antiretroviral Therapy
In an attempt to better understand the problem of non-adherence to HIV medications
a number of surveys have been conducted. The AIDS Clinical Trials Group

(ACTG)

conducted the first of these surveys and reported the results at the ICAAC meetings in 1997.

Seventy six patients enrolled in clinical trials across the country given a standardized
survey which included questions on why patiems were missing their medication. The results
are shown in Table 5.

Table 5: Reasons for Missing Doses of Antiretroviral Therapy (Chesney, 1997)

Reasons for Missing Doses
Simply Forgot
Slept through the dose
Away from home
Change in routine
Busy with other things
Too sick
Depressed

Proportion
40%
37%
34%
27%
22%
13%
9%

The survey also revealed characteristics of adherent versus non-adherent patients and
found that non-adherent patients were:
more likely to be working

younger age
depressed
feeling stressed
had pessimism about HIV disease
lower levels of coping efficacy.
more likely to consume greater quantities of alcohol (17 drinks per month versus 9
drinks per month)
Abstract Review from the Twelfth World AIDS Conference, Geneva Switzerland,
1998
The field of adherence to HIV therapies is still in its infancy. However, paced by the

rapid developmem of HIV therapeutics over the past few years interest in HIV adherence
has escalated. There has been little published research at this poim however, the Twelfth
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World Conference on AIDS represented the surge in interest with the submission of 146

abstracts with a main focus of adherence. In addition, adherence was memioned as a key
word in another 50 abstracts presented in Geneva. Table 6 represents a summary of abstract
characteristics presented in Geneva. Table 7 shows abstract subjects grouped by category.

Table 8 highlights the central issues and findings from Geneva and Appendix I summarizes
all abstracts on adherence.
Table 6: Summary of Geneva Abstracts

Subjects
Abstracts
Categories
Countries Submitting
research on adherence
Number of different
investigators
Total participant studied
Mean adherence

Total
130
8
18

122

23,790
54%

Table 7: Twelfth World AIDS Conference, Geneva, Switzerland. Abstracts by

Category:
Adherence Categories

Table
Abbreviation

General Adherence Overview G
C/P
Characteristics of nonand/or
adherent patients
incidence or prevalence of
non-adherence
I
Interventions/Strategies
Factors/Barriers

F

Adherence Assessment

A
CQ
T

Consequences
Adherence Theory
Costs of Non-Adherence

$$

Number of
Abstracts
Addressing Topic
2
35

54
49

11
4
4
1
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Table 8:Central Issues and Findings that Emerged from the Research Presented at
The Twelfth World AIDS Conference, Geneva Switzerland.

Reasons for Medication Non-Adherence
#1 forgot
#2 and # 3 side effects and fatigue

Difficulty concentrating
Determinants of Adherence
Participation in a clinical trial
Belief that the medication is working
Good social functioning
Perceived professional support

Older patients
Determinants of Non-Adherence

Youth

Changes in routine
Being away from home
The mid-day dose and weekend doses are most likely to be forgotten
Changes in routine contribute to non-adherence
More complex regimens
Regimens that require dietary restrictions
Longer duration of therapy
Side effects
Living alone
Alcohol and drug use may decrease adherence (not consistent)
Demographics do not predict non- adherence, although two studies found that adherence
was higher in men than in women
Poor relationships with providers
Regimens that are intrusive and disrupt normal activities
Patients who are non-adherent the day before seeing their provider are 9 times more
likely to have been non-adherent during the previous month
Interventions

Adherence is improved with family/friend / significant other support
Increased supervision
Early management of side effects
Evaluation of Adherence
Self reports of adherence are inaccurate
The combination of pill counts and prescription refills can be more useful assessment
tools if used in combination with indirect measures such as adherence questionnaires

BEHAVIORAL MODELS TO GUIDE THE PRACTICE OF THE
MEDICATION MANAGER
Models designed to understand and predict human behavior are rooted in

psychological theory. They attempt to provide a conceptual framework to guide the
interactions or practice with individuals. No single theoretical model of behavior fully fits
or explains the actions of people afflicted by a chronic disease.

However, although a single

model does not fully frame the challenges of adherence to HIV therapies, insight gained
from several models can be illuminating. In reading a review of various theoretical models
one may note the overlap in each of the models, none seeming perfectly discrete from

another.

This is in fact a reality as they have each been built on concepts identified in

previous models.

The Health Belief Model:

The Health Belief Model, developed in the 1950s by a group of social psychologists
at the US Public Health Service, was one of the earliest conceptual frameworks for

understanding why individuals did, or did not, practice a variety of health and medical
recommendations. (Rosenstock, 1974). Although it was originally designed to understand

prevention behaviors, it has evolved to include other time points in health decision making
such as screening, following medication regimens, keeping clinic appointments and other
health-related behavior.

It is presented here because of its concepts and role in the

foundation of future models and not necessarily for its practical applicability to behavior

change.
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The health belief model was developed out of the social-psychological theory that

encompasses value-expectancy in which, behavior is predicated from the value of an
outcome to an individual and from that individual’s expectation that a given action will

result in that outcome (Becker, 1976). The premise of the health belief model is that an
individual’s readiness to take action depends primarily on two variables: 1. The perceived
likelihood of being affected by an illness and how seriously it will affect him; 2. The
individual’s perception of the value of the proposed health behavior. If these assumptions
are correct then behavior would be based on the desire to avoid or improve illness and the

belief that a specific action would prevent or improve illness. In other words, what an

individual believes about his illness and its particular treatment has a strong influence on the
likelihood of adhering to that treatment. In the health belief model there are four elements,
which in their aggregate, explain health-related decision-making. These elements include:

(1) perception of the level of susceptibility (risk), this elemem is necessary but by no means
sufficient, requiring element (2) for action; (2) perception of the degree of severity of the
illness (consequences of contracting it or of leaving it untreated); (3) perception of the

health action’s potemial benefits (feasible and efficacious); and (4) benefits versus the
barriers of the treatment or therapeutic behavior (negative aspects include physical,

psychosocial, financial, inconvenience, side effects). Rosenstock viewed the perception of
susceptibility and severity as the impetus to act and the perception of benefits and barriers
as the path of action. He also asserted that health decisions need a stimulus or cue to trigger

the whole decision making process. This "cue to action" signals consciousness and can be

internally driven, by e.g. symptoms or externally driven, e.g., by doctor’s office reminder
cards or media information. The health belief model also recognizes the influence of other
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diverse variables that might influence a patient’s perception and therefore influence

decisions.
The correlation of the four elemems and adherent behavior has been the subject of
numerous research projects in the past 25 years. In a review of 46 studies of the Health
Belief Model, including 29 published since 1974, Janz and Becker use a significance ratio
to characterize the influence of Health Belief Model elements on health decisions. The

significance ratio was determined by dividing the number of positive, statistically
significant findings for each Health Belief variable by the total number of studies reporting
significance levels for that variable. In their review, studies were classified by behaviors
found at various phases of health and illness. These include preventive health behaviors;
illness behaviors, sick-role behaviors or clinic utilization behaviors.

Across the three classes of studies reviewed perceived barriers to adherence clearly
emerged as the strongest dimension of the Health Belief Model, transcending all phases of
health and illness, and providing valuable practical information for the developmem of an

adherence intervention. Although still significant, perceived susceptibility had a weaker
correlation to sick role behavior than the other dimensions and the threat of a severe illness
was not found to be a strong motivator for preventive behavior. Table 9 describes the

phases of illness and health studied under the health belief model. Table 10 shows
summary significance ratios for sick role, prevemive role and clinic utilization behaviors, as
well as significance ratios for sick-role and prevemive behaviors alone from the Janz and
Becker review for studies published after 1974.

41

Table 9" Phases of Illness and Health Studied under the Health Belief Model
Phase of Illness or
Health
Preventive health behavior
Clinic Behavior
Sick-role behavior
(includes diabetes,
hypertension, endstage
renal disease)
Illness behavior
Chronic Illness behavior

At risk health behaviors

Description

The diagnosis has already occurred.

Readiness to seek medical help and health care utilization
Applies to those in whom the incomplete resumption of
usual roles, residual disability, irreversible pathology,
and possibility of stigma is likely to occur.
Requires sick role behavior from a person who does not
feel sick. Has the duties of illness behavior but not the
privileges, such as reduced social obligations attached to
this state.

Table 10: Significance Ratios for Sick-Role Behaviors, Preventive Behaviors, And
Sick-Role/Preventative/And Clinic Utilization Behaviors

Susceptibility
73%

Severity
85%

Benefits

Barriers

75%

91%

Preventative
Behaviors

83%

36%

82%

100%

Sick role,

81%

65%

78%

89%

Sick-role behaviors

preventive role,
and clinic
utilization
behaviors

The health belief model has been criticized in its inability to uniformly correlate
beliefs with actions. Although many studies have documented significance to beliefs and

behavior, the literature is laced with contradictory conclusions concerning the relationship.

For example, Kirscht and Rosenstock cited significant relationships between perceived
susceptibility and adherence to an antihypertensive regimen while three nursing studies

42

found no significant correlation between health belief elements and compliance to

hypertensive regimens (Redeker, 1988).

Some of the health belief criticism stems from the fact that too much ofhealth belief
research has been retrospective. Another criticism stems from the use of diverse and

inconsistently reliable scales to measure relationship (Redeker, 1988). In particular, it has
been noted that beliefs that precede treatment versus beliefs during treatment do not

correlate with adherence.

This spurns the question of whether health beliefs cause

compliance or whether compliant behavior causes people to adapt certain beliefs. (Becker et

al., 1979). It could be interpreted that beliefs may be a necessary, but not always sufficient,
variable in behavior change.

However, there is enough evidence that assessment of health beliefs can guide
interventions aimed at improving adherence. By knowing which elements are below a level

necessary for adherence, the provider may be able to tailor an intervention to suit the needs
of that patient. In spite of contradictory evidence, it would seem that not knowing a

patient’s beliefs represents a handicap in creating an effective intervention.
Phases of health and illness that have been studied in the health belief model are described
in table 9. Different phases of health and illness have been studied separately because there
are different determinants needed to understand them. In attempting to understand HIV in

the context of the health belief model one is struck by the lack of a perfect fit. HIV is a
chronic disease yet often, at this point in the epidemic, without symptoms to trigger health

behaviors or to seek treatment. Perhaps a combination of "chronic disease" with "at risk".

analysis is best suited to individuals with asymptomatic HIV. To use the analysis of Kasl

(1974) in his review of the health belief model and behavior related to chronic illness:
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having asymptomatic HIV requires sick role behavior from a person who does not feel sick,
requires medication even though there is no change in health status and requires treatment
for an indefinite period of time. That situates people with HIV in a somewhat unique

position in our understanding of health beliefs and behavior.
The utility of a practical application of the health belief model is demonstrated by

Green et al. (1979) who used the findings of a survey of beliefs of outpatients with primary
hypertension to develop an intervention to improve health related actions. The survey
found that 70% of patients reported a lack of family support and understanding about their

health. Green then compared three interventions in 400 patients: an exit interview to
educate patiems about their medications, a home visit to increase family support, and a
small group discussion to empower patiems. The educational interview and the family
support intervention at home were found to be the most effective strategy to improve
medication adherence. The home visit alone achieved almost the same improvement in

adherence (Levine, 1979) as the two together.

The Health Decision Model:

The health decision model, developed by Becker during the 1980s, was an effort to build on
the health belief model and improve it (Eraker et al., 1984). It incorporates theories of
decision analysis and behavioral decision theory to develop a model of health decisions and

resultant behavior.

Decision analysis provides a means for patiems to express their

preferences about critical trade offs between benefit, risk, and sometimes about quantity and
quality of life. Behavioral decision theory identifies a number of general inferemial roles
that patiems use to reduce difficult mental tasks to simpler ones. The health decision model
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also recognizes the contributions of such factors as cultural beliefs, parem’s beliefs,

previous experience with illness, and information/misinformation given to them by nonmedical sources. One will notice that in the health decision model the elements of the

health belief model are framed differently for example benefits and barriers (risks) fall into
the category of patiem preferences. The health decision model incorporates findings of

years of research on barriers or factors that influence adherence, including the brevity of the
encounters with their provider and general satisfaction with their health care. In the Becker

model, a patient is more likely to adhere to medication regimens when he believes the
provider is correct, the illness can cause harm, and that the prescribed therapy will reduce
the complication or death, or his health will improve (Becker, 1979). Figure 1 demonstrates
the elements of the health decision model.
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Figure 1. The health decision model (Eraker et a1.1984, p261)
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Behavior Modification:

The term behavior modification is often associated with brain washing conditioning

techniques. We are reminded of Pavlov’s dogs and Skinner’s pigeons. However, behavior
modification is a collaborative effort, that recognizes that an individual’s behavior is
influenced by its antecedems (external and imemal events that trigger or elicit a behavior)

and consequences. Antecedents for example may include the sight of food for an individual
with a weight problem. An antecedem for not following a medication regimen may include
a sense of hopelessness about

one’s illness. Behavior modification involves identifying

behaviors that need to be changed and idemifying when they do and do not occur. In

addition, assessing, monitoring, and manipulating the impact of antecedent and consequent
events are also necessary in changing behavior. Some techniques employed in behavior

modification include:

Selfmonitoring:
One way that patients can be enlisted as collaborators in their health care is by teaching
them to self-monitor. Self-monitoring is a means of raising one’s consciousness and is
based on the premise that behavior change is unlikely to occur in the absence of an
awareness of the behavior.

Dunbar and Agras (1980) summarized guidelines, which can be used to increase
medication adherence using a behavior modification approach:
Ask the patient to self-monitor, by observing behaviors that have a positive
outcome
Use easy to use records
Ask the patient to assess readily observable behaviors
train the patient in self monitoring
Reinforce the patient’s accuracy in recording rather than any improvements or
changes in regimen related behavior
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Let patients know that their records will be checked for accuracy
Ask patients to record at the time the behavior occurs rather than at the end of the
day or the end of the week.
These guidelines were later supplemented by Friedman and Litt (1986)
Provide immediate feedback and encouragement to the patient about selfmonitoring.
Patients should eventually record behavior before rather than after it occurs
It is better to monitor a behavior than a goal.

Goal setting:
Goal setting is widely used in behavioral modification approaches. Again, the

patient is the key player in setting goals and working collaboratively in order to increase the
likelihood of their participation. Goals should be realistic and whenever possible people

close to the patient should be involved.

(Meichenbaum, 1.987).

Goals should be

moderately specific but not overwhelming. In addition, goals should lead to meaningful
rewards that can be offered as soon after the positive behavior as possible. Goals have been
described as homework assignmems and divided by devising the assignmem, presenting the

assignment, and monitoring the assignmem. (Martin and Washington).

Following

principles used in behavior modification, greater adherence to tasks will be achieved if the

patiem helps define the assignment.

The health care provider can further enhance

compliance by having the patient imagine ways in which the goals might not get completed.

It has been suggested that the provider might even have the patient practice the assignmem
in their office, but there is little doubt that this would be more effective if practiced in a

supervised fashion in the patient’s home environment. Success of goal completion must be
then attributed to the patient’s efforts and not a therapeutic technique (Meichenbaum, 1987).
Failure to achieve goals must be explored and even assessed in a health belief framework

of understanding the patient’s perception of the task.
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Corrective feedback:

Corrective feedback alone is not sufficient, but it is helpful when combined with self-

monitoring and goal setting relative to the patiems ability to adhere to treatment regimens.
Feedback should be accompanied by encouragement and perhaps additional training if
necessary.
Behavioral contracting
Behavioral contracting is a negotiated

agreemem between the patiem and the health care

provider that combines goal setting with reinforcemem and is conditional on achieving the

goal. It is an integral componem of the behavior modification process that actively involves
the patient in the decision making process. Central to the contracting process is the
identification of specific behaviors and how they might be carried out. Advocates of
behavior modification techniques suggest that behavior modification (medication

adherence) will be most successful and most durable when the patiem actually suggests the
specific imervemions that are to be undertaken. In order to accomplish this, however, the
health care worker must lay the groundwork by asking questions to engage the patiem in the
solution. This can be accomplished by exploring with the patiem those situations in which

he has not been able to adhere and identifying what is different about these situations.

Alternatively, the patiem can be given options from which to choose, which also serves to
increase the patient’s sense of personal control.

Unfortunately, evidence suggests that behavioral contracting may be effective only while it
is being monitored (Cummings et al., 1981), thus the provider should expect a long-term

relationship or a short-lived success. Other predictors of failure of behavioral contracts
include imposing contracts that are not negotiated with the patiem, not specifying provider
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responsibilities and not using reinforcemems.
Commitment enhancement."

Several measures have been proposed that are likely to enhance commitmem to medication

adherence (Meichenbaum, 1987):

Encourage patients to tell people about their commitment
Encourage specificity concerning the commitment, i.e. frequency, duration etc.
Solicit a commitment in oral and written forms.
Involve the patient in the choice of intervention.
Encourage patients to self-monitor their behavior
Positive behavior must be attributed to the patient.

Reinforcement."
Health related behaviors can be influenced by rewards and negative consequences.
Rewards can take the form of praise, public acknowledgemem or even food vouchers,
movie tickets, or lottery tickets. Negative consequences range from the removal of positive

reinforcement to the implementation of a deposit system, where patiems are required to

make a financial deposit which is refunded for adherem behavior. Self-reinforcement is a
third and perhaps more palatable measure to some than either rewards or negative

consequences. Self-reinforcement may include having patiems keep a flow chart of their
progress or in HIV care using critical laboratory values such as viral load. Again, inherent
in self-reinforcemem is the notion of the patient owning their success. Some have involved

family or friends in the reinforcement process for the provision of feedback as well as to
imegrate the behavior imo their normal lifestyle.

The Strengths Model:

During the case managemem years of the 1980s, the strengths model was developed by
Chamberlain and Rapp (Rapp, 1998) to help people with memal illness achieve goals that
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they set for themselves. The principles that serve as the underpinnings of the strengths
model are not only germane to those working with people with HIV, but can serve as a
sound basis for supporting adherence.

In the strengths model, case management services are tailored to the unique needs of each
person. Work is done and decisions are made with people, in a partnership, not to people,
while recognizing that all individuals are interdependem.

Principles of the Strengths Model (Rapp, 1998):
lo

he focus is on individual strengths rather than pathology.
Focus on what the cliem has achieved so far, what resources are currently available

to the cliem. This allows for a differem way of thinking about clients that recognizes their
own power to take care of themselves. It honors their skills, competencies and talents as

opposed to their deficits.
The community is viewed as an oasis of resources.

This principle speaks to the importance of the cliem’s environmem.

Each

individual’s community is unique and must be assessed and utilized as a source of strength

for that individual. The model supports the use of "naturally occurring resources, thereby

counting not only on the strengths of the individual but the strengths of those around them.
The case manager’s role under this principle is to be a catalyst for involving others in the
cliem’s life, that is to create collaborators.

3.

Interventions are based on client self-determination.

Cliems have the right to determine the form, the direction and substance of the case

managemem help. Case managers should do nothing

without the cliem’s approval,
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involving clients in all decisions. It is the case manager’s role under this principle to assess

strengths and work on behalf of the client to achieve the client’s goals. In understanding
why a cliem does not take their medication, for example, Rapp asserts that it is the only way
for them to express their opinion and exert their sense of power.

It sometimes requires the blending of strengths or guiding the cliem to recognize their own
strengths. The creation of new possibilities for the client is a contrast to talking them into
something. Reasonable and safe choices need to be presented so that the cliem can develop
the confidence of self-determination.
The case manager-client relationship is primary and essential.

Rapp describes the case manager-client relationship as the anchor during rough
and anxious times. It is the safety of the relationship that supports the client to cope with

the demands of change, new information, the environmem and other people. "The client
needs a traveling companion, not a travel agem (Rapp, 1998), "stressing the cooperative
nature of the client-case managemem relationship.

So

Aggressive outreach is the preferred mode of intervention.
Outreach imo the client’s own environment offers fertile ground for assessmem and

intervention. Office and telephone contact limits the information received to what the cliem

says in an artificial setting. Training skills inside a clinic or agency does not necessarily
transfer to the home setting. Amid the distractions of the home, skills that seemed well

integrated may be forgotten. The case manager can also use home visits to provide direction
to cliems, model behaviors and to teach others. The idemification of resources may also be

done best in the home environmem.
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People suffering from major mental illness can continue to learn, grow, and
change.
This aspect of the strengths model recognizes that the affliction is only one aspect of

the individual. "They, like us have a history of pain as well as accomplishmem, of talems
and foibles, of dreams and aspirations." A central tenant of the model is the belief in
individuals’ capacity to better their lives. The notion of "can do" must permeate the process

and relationships.

In summary, the roles of the case manager in the strengths model are:
Engagement and relationship, strengths assessment, personal planning, resource acquisition,
and collective, continuous collaboration and gradual disengagement.
The strengths model, although developed in the mental health community, is

generally founded on principles that strive to change behavior and improve lives. The
principles that have been used to empower individuals with mental illness transcend this
population and can be generalized for other purposes.

The Transtheoretical Model of Change:

The Transtheoretical Model of Change, developed by Prochaska (1983), is based on
an understanding that behavior change occurs in stages over time and that imervemions

cannot be successful unless the desire to change is internally driven and accepted. During

the process of change cognition and affect evolve. This theory has been applied successfully
to addiction behavior change, diet and weight control, exercise, screening and smoking

cessation. The focus of this model is motivational readiness or imention to modify problem

behaviors. Prochaska describes five stages of change through which individuals progress in
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the process of modifying their behavior: precontemplation, contemplation, preparation,
action and maintenance. Although these states represent a continuum, movement through

these states is not unidirectionional. In fact, the model is based on the inevitability that
individuals move back and forth, with relapse as an expected part of the process. Each

Stage of Change is characterized by conscious and unconscious thought processes and
strategies. Ten such processes of change have been identified which are thought to mediate
the transition to each stage. The association of stages, their processes, and appropriate
interactions are shown in Table 11.

Proponents of the model acknowledge the influence of pros and cons of change
throughout the process, noting that across studies, the pros are a stronger influence of
change than the cons. Prochaska viewed the pros as facilitators of change while the cons are
seen as barriers to change (Prochaska et al.,

1994).

Another important characteristic of this model, no doubt evolved from its

predecessors, is the emphasis on self-efficacy. Prochaska cites Banduras’ (1982) definition
of self-efficacy as a mediator between knowledge and action. In the transtheoretical model
of change, self-efficacy is felt to provide confidence to change. Confidence and temptation
are in a delicate balance across all stages of change.

The stages of change and their processes can guide the provider with appropriate

guidance based on the patient’s stage of readiness and can prepare the astute practitioner
for the inevitability of relapse.
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The Locus of Control Model:

The locus of control theory reflects the belief that the extent to which a person
perceives his ability to change or control his life impacts his willingness or ability to

comply with medical treatment. In this behavioral construct individuals are viewed as
internally oriented or externally oriented. Those who are internally oriented are believed to
be self-oriented and those who are externally oriented are influenced by others, the system
or fate. Simple statements like "the doctor says I have" versus

"I have a certain problem"

reflect internally versus externally oriented differences. There is evidence that imemally
oriented individuals may be less likely to smoke (Eiser et al., 1989) and more likely to have

had a recent pap smear (Bundek et al., 1993) or breast exam (Redeker, 1989). Furthermore,

given an external viewpoim, medication adherence is less likely. Those who are externally
based believe they have less control over their environmem.
Individuals of low socioeconomic status or members of minority groups are more likely to
exhibit external locus of control behavior. Therefore it is relevant medication adherence in
individuals with HIV infection, a disease which is known to be over-represemed in poor and

minority communities. "Continuous insults to personal integrity and dignity can predispose
individuals to attitudes of helplessness or fatalistic behaviors" (Hussey, 1989).

Locus of control is influenced by psychosocial factors (Hussey, 1989)"

1)
2)
3)
4)

Cultural-fatalism (feeling ostracized by society)
Lower socioeconomic status
Minority status
Familial reinforcement(a child who cominuously experiences disapproval or whose
wishes are chronically ignored learns that he cannot control his environmem or what
happens to him).
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Alternatively, factors that are associated with a positive locus of control include
ego-identity, self-worth, confidence, self-esteem and self-acceptance. Individuals who are
adherent to treatment regimens are often described as motivated.

The degree of

"motivation" exhibited by an individual may be a reflection of their locus of control beliefs.
Motivation is manifested by action in situations that are meaningful to an individual and
are influenced by social and cognitive factors as well as a sense of self-preservation. The

role of self-efficacy, in locus of control, is a relevant concept that links an individuals

feelings or thoughts about his own capability of accomplishing any given task to his actual
ability to achieve the goal (Bandura, 1981). Furthermore, if an individual believes that he
cannot achieve a goal, he is less likely to try. Alternatively, Banduras maintains that
individuals with stronger self-efficacy will exert a more active and persistent effort. In a

study designed to improve self-efficacy and self-esteem, Frank et al.(1995) demonstrated an
85% adherence rate and only a 10% drop out rate in a 3-year study of compliance in older

adults.
Buchmann (1997) suggested in "Adherence: a matter of self-efficacy and power"
that professionals can foster self-esteem by dividing recommendations into incremental

steps that can be mastered at pace comfortable for the patient.

Perhaps,

compartmentalizing the treatment experience at a controlled pace, individuals

unaccustomed to experiencing power and self-determination can have a successful
treatment experience.
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The Information, Motivation, and Behavior Model (IMB):

The IMB model, developed by Fisher and Fisher may be described as a second
generation model. Like to the transtheorectical model, it is built on its predecessors and is

very outcomes based. The model was bom after a thorough review of AIDS risk reduction
literature revealed that interventions that stressed information, motivation and behavioral
skills were more successful than those that did not. The review also led the creators to the
conclusion that the variables of information, motivation and behavior were the most sound

bases for intervention (Fisher and Fisher, 1992). Hence, they developed an AIDS risk
reduction model based on three determinants: Information, motivation and behavior where
information and motivation were felt to be the triggers for behavioral change and

maintenance. Fisher and Fisher poim out that information is a necessary but not sufficient
variable to behavior change and that an individual must also be motivated to effect a

change. This is substantiated by data that reveals that attitudes consistently predict their
practices (Fisher and Fisher, 1992). In the IMB model health beliefs are believed to be
determinants of motivation however the Fishers argue that other health belief variables,

such as susceptibility and severity are inconsistently correlated with risk reduction.
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Fisher and Fisher are currently developing an adaptation of the IMB model for

medication adherence which is summarized in Figure 2, with additions from Andrews in
italics. This proposed model may represent the most comprehensive understanding of

adherent behavior thus far. IMB reflects findings of HIV surveys, which identify barriers
to adherence as well as relevant characteristics of previous models, which can be

generalized to medication adherence. Constructs of the model demonstrate the

relationship of adherence information and adherence motivation to adherence behavioral
skills which are shown in relationship to actual adherence behavior and to medical
outcomes. As this is a work in progress, little has been said about context characteristics,
which curremly appear as independem variables.

Italicized entries represent Andrews’ modifications
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Table 12- Relevant Principles of Seven Behavioral Models in the Practice of

Improving HIV Adherence:

Model

Relevant Principles

Health
Belief
Model

Identify: patiems perceptions of illness and treatment, barriers including
fear of failure, sense of I can’t do it, I can’t afford it, I am not good
enough
Periodically ask patients "do you think this is working"
Expect barriers and work together on getting through them
Modify interventions to reflect patient preferences. Assess patient’s
perceptions of the benefits versus the risks
Learn about the patient’s cultural beliefs
Approach medication as a collaborative project with the patient as a key
Learn values and beliefs
Learn what behaviors need to be changed
Identify antecedems for non-adherent behavior
Identify vulnerable times for non-adherem behavior- when non-adherem
behavior does and does not occur
Have the patiem develop his own plan for achieving adherence
Have patient set their own goals involve loved ones in the patient’s
commitment to adherence
Have patient imagine ways that the goal might not be accomplished
Practice organizing medications and following a schedule, in the home
setting amidst normal distractions
Reward with immediate feedback, like timely enthusiastic reports of
viral load
It is better to monitor a behavior than a goal
Teach self-monitoring if appropriate.
Engage patient in discussion to identify situations in which they don’t
adhere
Attribute positive adherent behavior to the patient, not the intervention
Become the patiem’s cheerleader and work as a team to lower viral load
Reinforce positive adherence behavior-reward for X number of
undetectable viral loads (food vouchers, movie tickets, lottery tickets)
Work in partnership with the patient
Focus on individual strengths and achievements, not pathology
Honor skills and competencies and talents, not deficits
Identify collaborators
Use visits to the home for assessment, imervention, modeling behavior,
identifying resources, teach family/friends about patient’s treatmem and
the importance of adherence
Utilize community agencies for support
Exude a "can-do attitude"
Foster self-efficacy and power

Health
Behavior
Behavior
Mod

Strengths
Model
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Model

Locus of
Control

Relevant Principles
Recognition of locus of control may influence how providers
conceptualize patient’s response to treatment
Assess the patient’s beliefs in themselves and in their ability to achieve
adherence to medication regimen
Work with the patient to identify ways in which they already have
control over their behaviors and life (Taking care of children, getting to

appointments)
Identify who in the patient’s family or extended family and friends is
most supportive
Support self-efficacy
Transtheoretical
Model of

Change

Information
Motivation/

Behavior

Assess the stage of readiness
Tailor the intervention/interaction to the stage of readiness
Proceed cautiously at earlier stages
Review the pros and cons of treatment and adherence
Pros are a stronger influence than cons so frame adherence message as a
positive message, like eroticizing safer sex
Self-efficacy provides confidence to change. Build patients confidence
at every opportunity
Identify social support for change
Be aware of the ongoing and delicate balance of confidence versus
temptation. It looms until the final stages
Relapse is inevitable, be aware of the possibility particularly at certain
time points, have a relapse plan
Information and motivation are triggers for becoming adherem and
staying adherent
Information, motivation, and behavioral skills are all necessary for
adherence
Skills should be taught, rehearsed, and refined in a script-like fashion
Role-tlavin can helo to evaluate and imtrove skills

THE MEDICATION MANAGER
A Precedent for the Medication Manager: The Case Manager
The field of case management flourished in the memal health community during the
1970s when deinstitutionalization forced large numbers of people with memal illness out of
structured environmems into community based settings. The goal of deinstitutionalization
was to stabilize cliems with as few restrictions as possible. Economic pressure and the

developmem of psychotropic medication propelled the movemem faster than services could
be established. (Segal and Aviram, 1978). Cliems were left to negotiate the maze of
services in the community (Schwartz, Goldman, and Churgin, 1982). Delivery of services

became even more complex with the development of separate and fragmented programs.
Those most in need of services began to suffer at the hands of the evolving system. The

Community Support Program of the National Institute of Memal Health was the prototype
for the provision of case

managemem and supportive services in the early developmem of

these programs (Test and Stein, 1980). It provided the generic framework on which case
management models have been built (Bond et al., 1988). The issues of the mentally ill were

addressed by creating a case management system which encompassed two central features"

1) provision of individualized advice, counseling, and therapy to cliems in the community
and 2) linking cliems to needed services and supports in community agencies and informal

helping networks (Rothman, 1992). In 1974 the Child Abuse Prevemion and Treatmem Act
provided for case managemem in programs focused on abused children.

In the 1980s Dunst and Trivette proposed a case managemem model aimed at enabling
clients to solve problems, meet needs or achieve aspirations by promoting acquisition of
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skills that support and strengthen functioning to permit greater sense of individual or group

control (Dunst and Trivette, 1989).

Through the years the practice of case management has become incorporated into a
variety of fields including child welfare, community based long term care, severely
emotionally disturbed children and adolescems, substance abuse, disabled adults and

elderly, homeless and individuals with HIV and AIDS.
There is considerable variation of case management service provision across these
diverse populations. The backgrounds of case managers have been as varied as their roles,

including social work, psychology, nursing, and vocational rehabilitation. More recently
case managers working in the AIDS field have added even more diversity to the field.

Individuals with no previous training or experience grew into case management positions,
with a primary qualification of willingness to serve. Their enormous contributions to the

epidemic and to the lives of individuals with HIV have opened the minds of even the most
elite.

The roles of case managers in HIV care have included securing entitlemems,

arranging for wills and living wills, counseling on HIV disease and risk reduction, problem
solving, finding food, housing and shelter for those who need it. Working through issues of
childcare and custody with dying parents and arranging for medical care and medication

coverage. Many of those serving in this field have performed their responsibilities with
caring and commitmem with very little training. The field of HIV case management has
been a model for the next generation of health workers, the medication manager.
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The Theoretical Basis for the Practice of Medication Management
Rationale: The concept of .the medication manager is grounded in behavioral

theory, the literature on adherence in chronic diseases and on the most recem research on
adherence to antiretroviral therapy. Complex drug regimens are viewed as disruptive to
normal daily routines and may require significant adjustmems to lifestyle. Sometimes

simple factors in the patiem’s routine

prevem schedules from being followed.

Understanding patient’s beliefs about their illness and its treatment may shed valuable
light on targeting intervemions. Understanding a patiem’s worldview, their cultural

beliefs, their perception of themselves, and their abilities can also guide efforts to

improve adherence.

Many patiems state their reason for non-adherence as simply forgetting. Patients
who are successful in adhering to antiretroviral regimens state the need to develop a
routine and to establish cues in the course of their day. Helping the patient to identify

vulnerable times for non-adherence can be a proactive intervention. Organizing complex

regimens around meals and other medications is a daunting task for even the most

experienced pill taker. Many skills are necessary to organize and follow through on
taking a three-drug regimen that requires dosing two or three times a day carefully
scheduled around meals and other medications.

Data has been presented in this paper on the positive effects of increased support
and supervision, the value of home visits and the benefits of tailoring regimens to a

patiem’s lifestyle. It may greatly benefit the patiem and their ability to adhere to idemify
a support person that can help keep them on track.

However, the patiem may not have a
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willing or able individual to do this or may simply not be able to readily identify such a
collaborator.

As adherent behaviors form, timely feedback is valuable along with

reinforcement of positive behavior. Helping the patient to identify their strengths rather
than focusing on their weaknesses by .acknowledging successes contributes to self-

efficacy.
The role of the medication manager is to help the patient gain the skills necessary
to adhere to their complicated regimens and to help the patient believe in their ability to

carry out their goals. Early intervention to evaluate lifestyle as well as potential problems
in maintaining medication schedules is supportive of adherent behavior.

Ongoing

feedback and problem solving may prevent the loss of adherence and the loss of a viable
medication option. A liaison to provide timely feedback between the patient and provider
can prevem the patient from feeling overwhelmed about problems in adherence.

The Referral to the Medication Manager:

In an era of limited resources the medication manager must be used as effectively
as possible. Given a potential caseload of approximately 35-45 patients at a time it is

important to identify those patients who will benefit most from the time and skills of the
medication manager. One candidate for the services of the medication manager would be
a patiem who is highly motivated to be treated, believes that the medications will prevent

morbidity and mortality from AIDS, understands the consequences of non-adherence, but
does not necessarily have the skills to adhere to their regimen. Conversely, a patient who
is not ready to accept treatment and its burdens would not likely benefit from

interventions aimed at improving pill taking behavior.

Thus, screening patients to
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idemify appropriate referrals is an important component of an adherence enhancement
program.
The screening process must be realistic and not cumbersome yet effectively

identify traits of patients who are likely to benefit from adherence services. Ideally, the
screening will have a high degree of sensitivity, meaning that it will identify all those
who need the service most and a reasonable degree of specificity, meaning that it will
screen out those who are not ready for the service. During the screening process the

medication manager will need to ascertain if the patient is non-adherent, if they value

adherence, if they are ready to change their behavior and if they are at high risk for
disease progression.

One obvious criterion for referral to a medication manager would be the presence
of non-adherem behavior.

Unfortunately, evaluating medication adherence has

historically been and continues to be a complex and elusive problem. There are no

perfect qualitative nor quamitative measures for evaluating adherence. Even if one could
identify the presence of non-adherence the currently available techniques for assessing
how non-adherent are quite imprecise. Methods of assessing adherence have included

patient report, patient interview, coums of leftover pills and calculation of days between

prescription refills. Each of these methods alone offers limited information on a patient’s
medication adherence behavior. Serum drug levels have also been obtained in an attempt
to measure adherence but are generally best at approximating levels of drug taken during

the previous week. Medication adherence has also been studied using special medication
bottles that have been designed to record the time of a medication bottle opening. These
Medication Event Monitoring Systems (MEMS) have been devised specifically to
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observe pill-taking behaviors but can also be skewed by the simple act of opening the
bottle.
The Morisky Medication Adherence Scale (1986) is a four-item scale that has

demonstrated both concurrent and predictive validity with regard to antihypertensive

regimens. More recently this scale has been studied as a screening tool for antiretroviral

therapy adherence. The premise of the scale is that non-adherence is likely to take the
form of forgetting, carelessness, stopping the drug when feeling better or starting the drug
when feeling worse. The scale was designed to elicit "yes" answers which patients have
a tendency to favor when speaking with their health care provider.

The following

questions are included in the scale"

Do you ever forget to take your medicine:
Are you careless at times about taking you medicine?
When you feel better do you sometimes stop taking your medicine?
Sometimes if you feel worse when you take the medicine, do you stop taking it?

Each yes is given a score of 0 and each no is given a score of 1. A score of 0-1 is
considered a high score, 2-3 is considered a medium score and 3-4 is considered a high
score.

When using the scale as a predictor for hypertension control Morisky found that 75% of

the patients who scored high on the scale had their blood pressure under control at year 5,

compared with 47% under control for those who scored low.
Given the importance of idemifying those who need adherence enhancemem
services most a score of 2 can be used as a trigger for only moderate adherence and

specific areas of deficit can be targeted for intervemion.

Other measures of adherence can be employed at the screening process as part of a
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multifactorial process.

These should include a self report of adherence during the

previous week and an assessment from the patiem’s provider.

A second important area of screening is the patiem’s readiness for adherence and
intervemion. This can be ascertained by applying a combination of patiem beliefs with

the transtheoretical model of change to the screening process. The interventions applied

through the medication manager are intended to target those who are at least
contemplating if not preparing for adhering to antiretroviral regimens.

In the

contemplation stage of change the medication manager may have limited impact on
adherence behaviors. Patients who are referred in the preparation stage can benefit from
a health professional who can identify strengths and past successes, begin to teach them

adherence skills and help them identify support. Specific imeractions in later stages are
also idemified in Table 11.
The patients preferences and goals must be included in an assessment by the
medication manager.

This impacts their motivation and readiness and should be

specifically addressed in a screening interview.
Another factor in evaluating the appropriateness of a medication manager referral
is risk for disease progression. This can be determined by viral activity, based on viral

load and CD4

coums. Although adherence is

no less important for those with low or

undetectable viral loads these patients may choose to wait for treatment or choose simpler

protease sparing regimens.

Logistics of the Medication Manger Practice:
The medication manager is a health professional who does not necessarily have a
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nursing background or a pharmacy background. This individual will work closely with
the provider and other members of the health care team to improve adherence behaviors
and will not be responsible for prescribing or changing medication regimens in any way.
Given the medication managers central role in orchestrating the adherence effort and the

importance of working closely with other members of the health care team, the
medication manager will ideally be located in an HIV clinic. This will afford maximal

supervision and opportunities for this para-professional and will enhance communication
and the multidisciplinary effort of the program. Supervision is an important feature of the
medication manager program and would be appropriately administered by a clinic nurse
or physician.

Funding the Medication Manager Program:

Funding of the medication manager program could come from three distinct
sources. These include the state via the legislature, national funding via the Ryan White

program, or privately via the pharmaceutical industry or private foundations. There is

currently a proposal being developed to ask for funding from the state in this legislative
session. A proposal has also been drafted to seek funding from the pharmaceutical

industry. This option seems particularly viable in light of the benefits for drug companies
who would gain from patients taking their medication. The following is a proposed

budget outlining the costs of training, supervision, salary and benefits for 10 medication
managers for the state of Connecticut.
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Proposed Budget:
Item
Medication manager

CostM
$50,000

Number of Positions
10

Total

$7,500 (15%)

10

$75,000

$10,000

10

$100,000

$1,000/MM

10

$10,000

$500,000

(MM) salary, benefits,
and overhead
Administrative
overhead
Program costs
(brochures, pill boxes,
etc.) per site
Medication manager
Training Program
Clinical Supervision
Total

$ 3,000/year/MM

$30,000
$715,000

The Principles and Practice of the Medication Manager:

From extensive review of the adherence literature as well as from behavioral
theory the principles and-practice of the medication manager have been outlined.
Principles:

Work in partnership with the patient.
Focus on individual strengths and achievements.
Adherence behavior is driven by information and motivation.
Honor skills, competencies, and talents.
Exude a "can do" attitude.
Foster self-efficacy and power.
Recognize the contribution of the patient’s beliefs in the treatment and in their ability to
adhere.

Expect barriers.
Monitor behaviors, not goals.
Attribute positive behavior to the patient
Practices:

Identify:
The patient’s perceptions of illness, treatment, and barriers to adherence.
Readiness for treatment and adherence
Patient preferences
Vulnerable times for non-adherent behavior.
Give information that is clear, written, and non-technical.
Teach behavioral skills.

71

Use return demonstration to evaluate adherence.
Tailor the regimen to the patient, not the patient to the regimen.
Have the patient develop their own goals and plan for achieving adherence.
Have the patient practice organizing their medications and following a schedule in the
home setting.
Provide immediate feedback.
Identify collaborators and a support network.
Use visits to the patient’s home for assessment, intervention, and identifying resources.
Follow up with the patient at designated intervals.
Use adherence tools-reminders, cues, and organizers.
Contribute to patient satisfaction by acting as a liaison with the provider.

Each patiem referred to the

medication manager will be viewed as an individual

with unique needs and circumstances. Therefore, the principles will remain consistent

but the specifics of the practice will vary depending on the needs of the patient. Nonadherence in a patient who has a good support system but can not remember to take their
medication will call for a different intervention than a patient who is homeless and non-

adherent. The response to non-adherence also must vary depending on the patient’s

strengths, knowledge, and skills. The algorithm in Figure 3 serves as a guide for
individualized medication management.
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Medication Manager Job Description:

1. Assess patient environmental, lifestyle, and functional barriers to adherence. Assess
knowledge and motivation.
a. Home visits as necessary.
2. Develop an adherence support plan based on patient strengths
a. Reinforce patient understanding of disease process and the relationship of
adherence to viral resistance.
b. Develop realistic medication schedule,
c. Work with patient to implement support system.
d. Teach patient adherence skills.
e. Assist patient to idemify and manage impact of cultural beliefs on compliance
3. Monitor adherence and identify problems.
a. Document adherence and adherence problems (pill counts, patient reports, etc)
4. Serve as a liaison between patient and provider.
a. Notify provider of adherence problems and side effects.
b. Foster communication between the patient and the provider.
c. Accompany patient to medical visits as requested by patient.
5. Work collaboratively with other members of the health care team as needed.
6. Maintain database of additional available support services.
7. Document outcomes of services to patients
a. Develop database of patients served
b. Track and idemify barriers to care. Other duties as necessary.

Anticipated Workload"
Follow 35-45 patients for up to 12 weeks with subsequem quarterly monitoring for up to
1 year. Minimum of one home visit per patient (when possible) to perform an initial
assessmem and develop an adherence plan. Minimum of weekly comact; more if
necessary.
Qualifications:
Required: Excellent communication and interviewing skills. Creative problem solving
skills. Flexibility. Non-judgmental attitude. Good people skills. Good judgement.
Desired:

Knowledgeable about HIV. Previous experience with HIV patients. Bi-lingual/bi-cultural.
Experience working with addicts. Ability to assimilate rapidly changing medical
information. Well organized. Own transportation. Health education or allied health
background. Knowledge of basic medical terminology. College education or
paraprofessional certificate.

A Case Study: Carmen and Albert
This thesis has illuminated the problems encountered in antiretroviral adherence
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and has laid the foundation for the creation of a member of the health care team who can

support adherence behaviors. As I wrote this paper I utilized the concepts, imagining

myself as the medication manager, using newly gained knowledge to improve the
adherence of the patients I follow in clinical trials. I would like to briefly share my
experience with Carmen, one of the patients I follow. Carmen is a 26-year-old Latina
woman from Bridgeport who was diagnosed earlier this year with HIV infection. She
was asymptomatic and followed by a nurse practitioner in Bridgeport. Carmen came to

Yale to be evaluated for participation in an antiretroviral clinical trial. She had a mid

range viral load of 32,241 copies and a CD4 count of 375 and she had never been treated
for HIV before. Her affect appeared giddy and flip, yet she had a serious concem about
her health. In April we enrolled her in a study examining the safety and efficacy of a

triple combination of nelfinavir/AZT/and 3TC. Carmen was on medication for 6 months
when I inherited her as a study patient. In routine questioning about her adherence, she
admitted that it had only been fair. This was supported by her fluctuating viral load and

by the number of pills left in her medication bottles, which she dutifully brought to her
study visits. In October, on her week 24 visit on study I decided to focus intensively on
her medication adherence. I asked her to come in every four weeks so that we could
work on her adherence, rather than every 8 weeks, according to protocol. I also asked her
to bring her significant other to her next visit. When Carmen and her boyfriend, Albert,
came for her visit, we spent several hours working on her adherence. We talked about

how she felt about her medications. She told me how she hated the "nasty blue pills."
She never called them by name, always the "nasty blue pills." I asked her to tell me what

she does each minute of her day, beginning with her waking up. I wrote her schedule in
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great detail, including her medication dosing times. I referred to her nelfinavir as the

nasty blue pills, the 3TC as white diamonds, and the AZT as white circles, just as she
does. I learned what was important to her during her day and I listened carefully to her
responsibilities and became aware of her need for more control in her life. She told me

that when all her responsibilities were done, she liked to go out at night. I asked her tell
me which doses were hardest to take. It was of course the doses that fell during the time

when she liked to go out. I involved her boyfriend Albert in the discussion and asked her
and Albert to try and figure out how she could remember to take more of her pills. I
witnessed them creating a plan and I supported their decision. They determined that the

morning was a time that Carmen was faithful about taking her pills. They decided that

when Carmen takes her moming pills she should also put the rest of the day’s pills in a

pouch, so that no matter where she was, she would have her pills with her. They also
decided that she would fill an additional pouch with a one-day emergency supply of pills.

They idemified that no matter what Carmen is doing, she always carries her black
knapsack. This was a safe place to keep the pills. I wrote down what Carmen and Albert
had agreed to do to improve Carmen’s adherence. I asked Carmen to sign the plan,

indicating that she understood what she had agreed to do. I asked them to come back in
four weeks for Carmen’s regular study visit. They returned in four weeks and reported
that things had gone much better. Carmen’s viral load results arrived this week. Her
viral load is below the limits of detection, for the standard assay, which measures down to

400 copies as well as by ultra sensitive assay, which measures down to less than 40

copies. I immediately called Carmen, to share the good news and to praise her for her
hard work. This case

represems

a successful moment in a therapeutic relationship.
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Again, we will not wait 8 weeks as required by the protocol. Carmen will return in 4

weeks to reinforce the process.

Key points about this intervention are supported by the literature. These include:
More frequent visits
Eliciting beliefs about her medicine.
Identifying problem times.
Involving a support person
Showing respect.
Having the solution come from the patient
Having Carmen sign the plan, creating a behavioral contract.
Immediate feedback upon receiving her viral load results. Behavioral "cheerleading", an
important concept in supporting adherence.
Giving Carmen the credit for improving her adherence.
Improving Carmen’s adherence was easy due to the solid support of her boyfriend.

Most patiems, however, do not have so easily idemified a person who is as invested as
Albert in their care. There isn’t anything that I did to help Carmen with her adherence that
needed to be done by a nurse. On the other hand, there are few physicians who have the
time to spend several hours with a patient. Under normal clinic conditions it would also

have been impossible for a clinic nurse to have the time necessary to carefully evaluate and

implement a plan to improve adherence.

Training the Medication Manager: A Curriculum

A curriculum has been designed based on review of the adherence literature and review of
theoretical models of behavior. Relevant concepts from both have been translated into
curriculum contem. Training of the medication manager will emphasize respect of the

cliem, and an understanding of the difficulties of organizing ones life around complex but

life-saving medication regimens. Medication managers will be taught skills of assessment,

problem solving, and client education methods.

They will also be given sufficiem
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information on HIV infection and its treatment as well as the factors affecting adherence
Week I
General HIV Overview:
Basics of the immune system (including T cells and their role, meaning of T cell

counts)
Pathogenesis (viral life cycle, concepts of replication, meaning of viral load)
Natural History (Seroconversion and Primary Infection, Asymptomatic infection,
Progression, and AIDS)
Clinical Picture (Symptoms associated with HIV, what do T cell counts tell us about
risk of infections, Major opportunistic infections)
Week II

HIV Treatment Strategies-Part I
Basic concepts of HIV care
Understanding HIV treatmem approaches (including concepts of combination
therapy, HAART)
Classes of HIV Medications"
NRTIs, NNRTIs, Protease Inhibitors, Immune Based Therapies
Treatmem of Opportunistic Infections
Week III

HIV Treatment Strategies-Part II
Specific medications
Medication actions, medication side effects
Medication imeractions:
Drug:Drug imeractions, Drug:Food Imeractions
Concepts of Resistance-simplified
Mutations to Resistance 101

Week IV
Adherence
* Why is adherence important?
Why is adherence difficult?
Issues/Barriers
in medication adherence (Patiem, Provider, Environmemal)
*
Exploring cultural issues that relate to adherence
Human Behavior 101
Week V

Integrating theoretical models into the practice of the medication manager
Brief summary of behavioral models and what we have learned from them
Health Belief/Decision Model
Locus of Control Theory
Strengths Model
Transtheoretical Model of Change
Information, Motivation, Belief
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Week VI
Patient assessment
Beliefs and attitudes about HIV and treatment

Identifying strengths
Identifying weaknesses and vulnerable times
Evaluating the environment, adherence potential, lifestyle, adherence support and
functional barriers to adherence
Tailoring, medication scheduling, and organization
Developing an adherence support plan-who can help, how can they help, when can
they help
Evaluating needs for support (including how often to contact the patient)
Strategies for improving medication adherence
Monitoring adherence
Week VII
Patient education strategies-part I (What does the patient need to know)
General HIV information, side effects, drug interactions, food interactions
Teaching patient adherence skills
Supporting patient/provider communication
Week VIII
Patient education strategies-part II
* How to involve your patient in the adherence process
Role play
Adherence problems (what are the signs and what to do when a problem is identified)
Trouble shooting adherence problems (including when and how to call the provider)
How to serve as a liaison between your patient and their provider
Resources to assist medication managers

.

CONCLUSION
Non-adherence to antiretroviral therapy has been well-documemed (Chesney,

1998; Gallant and Block, 1998; Johnston, 1998; Jiminez-Nacher, 1998). As HIV evolves
imo a chronic manageable disease the importance of medication adherence comes into

light. While the study of adherence in HIV disease is in its infancy much has been
learned about adherence from other chronic diseases, which can be applied to adhering to
antiretroviral therapy.

Medication adherence is known to be a factor of numerous

variables including beliefs, preferences, readiness, social support, and relationship with

provider. Information is necessary but not sufficiem to assure adherence. Adherence
also requires organizational and behavioral skills to be able to establish a medication

taking routine.

Currently, adherence issues are generally addressed by the provider in the form of
a question directed at a patient. There is conclusive evidence that the information gained

by self-report is often inaccurate. This question may be followed-up by the adjustment of
the medication schedule or perhaps a switch to a differem regimen which seems to fit the

patient’s needs. This approach is unlikely resolve adherence issues given the limited
question and answer approach that is feasible during a busy clinic session.
The literature has shown that single imerventions to enhance adherence each have
a small effect size and make little difference in overall adherence behavior. Adherence

can be improved, however, with a combination approach utilizing educational,

behavioral, and educational modalities. The existing HIV health care system is already

stressed and can not provide patients with the added attemion necessary to carry out a

comprehensive plan to improve adherence. It is not only feasible but also important that
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components of adherence enhancement become incorporated into the daily activities of

providers. However, the magnitude and complexity of the adherence problem in the
treatment of HIV disease is significant and warrants a comprehensive and organized

approach.
This thesis proposes that the issues of adherence in individual patients can be

managed best by the creation of an instrument that can enable us to apply the principles
and practices identified to improve adherence. In this model a health care professional,
called a medication manager, would become knowledgeable in evaluating factors which
influence adherence and teaching behavioral skills necessary to take antiretroviral

medications as prescribed. The medication manager would become the co-orchestrator of

the adherence effort, acting in partnership with the patient and their physician. The
medication manager would be trained to focus on influencing adherence behavior. This

requires an ability to assess patiem circumstances and attitudes, apply principles of
behavior change and identify cues and supports to help patients adhere.

It is recognized that this model would require additional financial resources not
currently available for the addition of a new health care position. It could be argued that
we cannot justify the addition of a new health care professional in today’s health care

environment. There is also no data to support a cost:benefit argument in favor of a

medication manager program. However, it is known that enormous resources have

already been expended to develop medications to treat HIV infection. The failure of
these medications and greatest waste of precious resources is largely related to patients
not being able to take antiretroviral medications as prescribed. Before we judge our

patiem’s value of medication adherence it may be important to begin by evaluating our
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own value of adherence. It is our failure to adequately address issues of adherence that

sends an important message to our to our patients and determines our committment to the
future of HIV care.
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